Nonsteroidal antiinflammatory drug use in patients receiving warfarin

Emphasis on nabumetone

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Phenylbutazone has been clearly demonstrated to interact pharmacokinetically and clinically with warfarin, although several other nonsteroidal antiinflammatory drugs (NSAIDs) also have the potential to interact with warfarin to cause alterations in prothrombin time. Aspirin is known to inhibit platelet aggregation irreversibly, whereas nonaspirin NSAIDs are thought to inhibit platelet aggregation reversibly. In contrast, nabumetone was not shown to cause significant inhibition of platelet aggregation, which may be related to the fact that nabumetone preferentially inhibits the prostaglandin synthase-2 isozyme instead of the prostaglandin synthase-1 isozyme. Furthermore, in studies in patients and normal volunteers stabilized on warfarin, nabumetone did not cause alterations in the prothrombin time or international normalized ratio. Based on data evaluating the concomitant use of nabumetone and warfarin, the relative lack of platelet inhibition, and the relatively lower risk of nabumetone-induced gastrointestinal mucosal damage as assessed by radiolabeled chromium-51 fecal blood loss studies and endoscopic evaluations, nabumetone may be preferred if concomitant therapy with warfarin is indicated.

Original languageEnglish
JournalAmerican Journal of Medicine
Volume95
Issue number2 A
DOIs
StatePublished - Aug 9 1993

Fingerprint

nabumetone
Warfarin
Anti-Inflammatory Agents
Platelet Aggregation
Pharmaceutical Preparations
Prothrombin Time
Prostaglandin-Endoperoxide Synthases
Isoenzymes
Phenylbutazone
International Normalized Ratio
Chromium
Aspirin
Healthy Volunteers
Blood Platelets

All Science Journal Classification (ASJC) codes

  • Nursing(all)

Cite this

Nonsteroidal antiinflammatory drug use in patients receiving warfarin : Emphasis on nabumetone. / Hilleman, Daniel E.; Mohiuddin, Syed M.; Lucas, B. Daniel.

In: American Journal of Medicine, Vol. 95, No. 2 A, 09.08.1993.

Research output: Contribution to journalReview article

@article{14c287c4979c4e75bb76fdab165c8781,
title = "Nonsteroidal antiinflammatory drug use in patients receiving warfarin: Emphasis on nabumetone",
abstract = "Phenylbutazone has been clearly demonstrated to interact pharmacokinetically and clinically with warfarin, although several other nonsteroidal antiinflammatory drugs (NSAIDs) also have the potential to interact with warfarin to cause alterations in prothrombin time. Aspirin is known to inhibit platelet aggregation irreversibly, whereas nonaspirin NSAIDs are thought to inhibit platelet aggregation reversibly. In contrast, nabumetone was not shown to cause significant inhibition of platelet aggregation, which may be related to the fact that nabumetone preferentially inhibits the prostaglandin synthase-2 isozyme instead of the prostaglandin synthase-1 isozyme. Furthermore, in studies in patients and normal volunteers stabilized on warfarin, nabumetone did not cause alterations in the prothrombin time or international normalized ratio. Based on data evaluating the concomitant use of nabumetone and warfarin, the relative lack of platelet inhibition, and the relatively lower risk of nabumetone-induced gastrointestinal mucosal damage as assessed by radiolabeled chromium-51 fecal blood loss studies and endoscopic evaluations, nabumetone may be preferred if concomitant therapy with warfarin is indicated.",
author = "Hilleman, {Daniel E.} and Mohiuddin, {Syed M.} and Lucas, {B. Daniel}",
year = "1993",
month = "8",
day = "9",
doi = "10.1016/0002-9343(93)90394-5",
language = "English",
volume = "95",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "2 A",

}

TY - JOUR

T1 - Nonsteroidal antiinflammatory drug use in patients receiving warfarin

T2 - Emphasis on nabumetone

AU - Hilleman, Daniel E.

AU - Mohiuddin, Syed M.

AU - Lucas, B. Daniel

PY - 1993/8/9

Y1 - 1993/8/9

N2 - Phenylbutazone has been clearly demonstrated to interact pharmacokinetically and clinically with warfarin, although several other nonsteroidal antiinflammatory drugs (NSAIDs) also have the potential to interact with warfarin to cause alterations in prothrombin time. Aspirin is known to inhibit platelet aggregation irreversibly, whereas nonaspirin NSAIDs are thought to inhibit platelet aggregation reversibly. In contrast, nabumetone was not shown to cause significant inhibition of platelet aggregation, which may be related to the fact that nabumetone preferentially inhibits the prostaglandin synthase-2 isozyme instead of the prostaglandin synthase-1 isozyme. Furthermore, in studies in patients and normal volunteers stabilized on warfarin, nabumetone did not cause alterations in the prothrombin time or international normalized ratio. Based on data evaluating the concomitant use of nabumetone and warfarin, the relative lack of platelet inhibition, and the relatively lower risk of nabumetone-induced gastrointestinal mucosal damage as assessed by radiolabeled chromium-51 fecal blood loss studies and endoscopic evaluations, nabumetone may be preferred if concomitant therapy with warfarin is indicated.

AB - Phenylbutazone has been clearly demonstrated to interact pharmacokinetically and clinically with warfarin, although several other nonsteroidal antiinflammatory drugs (NSAIDs) also have the potential to interact with warfarin to cause alterations in prothrombin time. Aspirin is known to inhibit platelet aggregation irreversibly, whereas nonaspirin NSAIDs are thought to inhibit platelet aggregation reversibly. In contrast, nabumetone was not shown to cause significant inhibition of platelet aggregation, which may be related to the fact that nabumetone preferentially inhibits the prostaglandin synthase-2 isozyme instead of the prostaglandin synthase-1 isozyme. Furthermore, in studies in patients and normal volunteers stabilized on warfarin, nabumetone did not cause alterations in the prothrombin time or international normalized ratio. Based on data evaluating the concomitant use of nabumetone and warfarin, the relative lack of platelet inhibition, and the relatively lower risk of nabumetone-induced gastrointestinal mucosal damage as assessed by radiolabeled chromium-51 fecal blood loss studies and endoscopic evaluations, nabumetone may be preferred if concomitant therapy with warfarin is indicated.

UR - http://www.scopus.com/inward/record.url?scp=0027179593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027179593&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(93)90394-5

DO - 10.1016/0002-9343(93)90394-5

M3 - Review article

VL - 95

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 2 A

ER -